Compare WEST & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEST | CBIO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | 1408 | 44 |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.7M | 340.4M |
| IPO Year | N/A | N/A |
| Metric | WEST | CBIO |
|---|---|---|
| Price | $3.85 | $13.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 373.9K | 160.9K |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.19 | N/A |
| Revenue Next Year | $10.74 | $355.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.59 | $8.72 |
| 52 Week High | $7.92 | $17.39 |
| Indicator | WEST | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 61.03 |
| Support Level | $3.62 | $11.88 |
| Resistance Level | $4.69 | $13.36 |
| Average True Range (ATR) | 0.25 | 1.01 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 8.63 | 82.17 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider in the U.S, providing coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice and restaurant, convenience store and travel center, non-commercial account, CPG, and hospitality industries around the world. The company's segment includes Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.